All In Biotech

Drug Trial Radar · NCT06226805

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

A Multicenter, Double-blinded, Placebo-controlled, Single Ascending Dose, Two-part, Randomized, Phase 2 Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BB-031 in Acute Ischemic Stroke Patients

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Jun 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Basking Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.

Conditions

  • Acute Ischemic Stroke

Interventions

  • BB-031Drug

    Solution for injection

  • PlaceboDrug

    0.9% sodium chloride for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptomatic Intracranial Hemorrhage (sICH)Time frame: 24 hours

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • HonorHealth Bob Bove Neuroscience Institute

    Scottsdale, Arizona · Recruiting

  • Mills Peninsula Medical Center

    Burlingame, California · Withdrawn

  • MemorialCare Long Beach Medical Center

    Long Beach, California · Withdrawn

  • California Pacific Medical Center

    San Francisco, California · Withdrawn

  • Pacific Neurosciences Institute at Saint John's Physician Partners

    Torrance, California · Recruiting

  • Baptist Health Medical Center

    Jacksonville, Florida · Terminated

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Cooper University Hospital

    Camden, New Jersey · Recruiting

  • WakeMed

    Raleigh, North Carolina · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • ProMedica Toledo Hospital

    Toledo, Ohio · Recruiting

  • Mercy Health St. Vincent Medical Center

    Toledo, Ohio · Recruiting

  • Valley Baptist Medical Center - Harlingen

    Harlingen, Texas · Recruiting

  • Memorial Hermann Hospital

    Houston, Texas · Terminated

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Monash Medical Centre

    Clayton, Victoria, Australia · Terminated

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • University of Alberta Hospital

    Edmonton, Alberta, Canada · Recruiting

  • Vancouver Stroke Program

    Vancouver, British Columbia, Canada · Recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.